<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(2)</volume><submitter>Marrocco R</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Immunotherapy has had limited success in pancreatic cancer, largely due to a low mutational burden and immunosuppressive microenvironment. Here we hypothesized that systemic delivery of viral antigens can redirect pre-existing antiviral immunity against pancreatic tumors.&lt;h4>Methods&lt;/h4>Cytomegalovirus (CMV, a β-herpesvirus) was chosen, as the majority of the population is infected and it induces an extremely large/broad memory T-cell response. Mice latently infected with murine CMV (MCMV) were orthotopically implanted with pancreatic cancer cells and treated with systemic injections of MCMV T-cell epitopes. Tumor growth was monitored by ultrasound two times a week, and immune cell infiltration was analyzed by histology, flow cytometry and single-cell RNA sequencing (scR</pubmed_abstract><journal>Journal for immunotherapy of cancer</journal><pagination>e012969</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12927352</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Redirecting cytomegalovirus immunity against pancreas cancer for immunotherapy.</pubmed_title><pmcid>PMC12927352</pmcid><pubmed_authors>Gulay K</pubmed_authors><pubmed_authors>Maia C</pubmed_authors><pubmed_authors>Lowy A</pubmed_authors><pubmed_authors>Martsinkovskiy A</pubmed_authors><pubmed_authors>Jaljuli M</pubmed_authors><pubmed_authors>Lucero-Meza E</pubmed_authors><pubmed_authors>Salu P</pubmed_authors><pubmed_authors>Mose E</pubmed_authors><pubmed_authors>Benedict C</pubmed_authors><pubmed_authors>Sun S</pubmed_authors><pubmed_authors>Hurtado de Mendoza T</pubmed_authors><pubmed_authors>Marrocco R</pubmed_authors><pubmed_authors>Brunel S</pubmed_authors><pubmed_authors>Patel J</pubmed_authors><pubmed_authors>Medari R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Redirecting cytomegalovirus immunity against pancreas cancer for immunotherapy.</name><description>&lt;h4>Background&lt;/h4>Immunotherapy has had limited success in pancreatic cancer, largely due to a low mutational burden and immunosuppressive microenvironment. Here we hypothesized that systemic delivery of viral antigens can redirect pre-existing antiviral immunity against pancreatic tumors.&lt;h4>Methods&lt;/h4>Cytomegalovirus (CMV, a β-herpesvirus) was chosen, as the majority of the population is infected and it induces an extremely large/broad memory T-cell response. Mice latently infected with murine CMV (MCMV) were orthotopically implanted with pancreatic cancer cells and treated with systemic injections of MCMV T-cell epitopes. Tumor growth was monitored by ultrasound two times a week, and immune cell infiltration was analyzed by histology, flow cytometry and single-cell RNA sequencing (scR</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-07-16T18:26:32.348Z</modification><creation>2026-07-09T11:14:25.838Z</creation></dates><accession>S-EPMC12927352</accession><cross_references><pubmed>41638871</pubmed><doi>10.1136/jitc-2025-012969</doi></cross_references></HashMap>